Anti-trypanosomal activity of secnidazole in vitro and in vivo by Eke, Ifeanyi G et al.
Eke et al 
Trop J Pharm Res, March 2017; 16(3): 535  
 
Tropical Journal of Pharmaceutical Research March 2017; 16 (3): 535-541 
ISSN: 1596-5996 (print); 1596-9827 (electronic) 
© Pharmacotherapy Group, Faculty of Pharmacy, University of Benin, Benin City, 300001 Nigeria.  
All rights reserved. 
 
Available online at http://www.tjpr.org 
http://dx.doi.org/10.4314/tjpr.v16i3.6 
Original Research Article 
 
 
Anti-trypanosomal activity of secnidazole in vitro and in 
vivo 
 
Ifeanyi G Eke1*, Ikenna O Eze2, Terry A Ezeudu2, Ukamaka U Eze3, Aruh O 
Anaga1 and Patrick A Onyeyili4 
1Department of Veterinary Physiology and Pharmacology, 2Department of Veterinary Parasitology and Entomology, 
3Department of Veterinary Medicine, Faculty of Veterinary Medicine, University of Nigeria, Nsukka, 4Department of Veterinary 
Physiology and Pharmacology, Faculty of Veterinary Medicine, Federal University of Agriculture, Makurdi, Nigeria 
 
*For correspondence: Email: Ifeanyi.eke@unn.edu.ng; Tel: +2348037494699 
 
Received: 18 March 2016        Revised accepted: 22 September 2016 
 
Abstract 
Purpose: To evaluate the anti-trypanosomal effect of secnidazole (SEC) in vitro and in vivo.  
Methods: The dose-response effect of SEC in Trypanosoma b. brucei infected rats was evaluated in 
five groups of rats (n = 5). Group A was infected but untreated; B was given diminazene aceturate (DA) 
(3.5 mg/kg) intraperitoneally, while groups C, D and E received orally 400, 800 and 1600 mg/kg of SEC, 
respectively.  The effect of a combination therapy of SEC and DA was studied in 7 groups of rats (n = 
5). Group 1 was infected but untreated; groups 2 – 7 were treated with DA (3.5 mg/kg), while groups 3 – 
7 received in addition to DA, increasing double doses of SEC (50 – 800 mg/kg).  
Results: The MIC of SEC and DA were 1.4 and 0.0021 mg/ml respectively. SEC dose-dependently and 
significantly (p < 0.05) lowered parasitemia from day 2 post-treatment (PT) compared with infected 
untreated rats. Parasitemia was cleared 3 days PT in all combination groups and 5 days PT in DA 
group. Relapse of infection occurred in Group 2, 13 days PT, and 16 and 27 days PT in Groups 3 and 4 
respectively. There was no relapse of infection in Groups 5 – 7 up to 70 days PT.  
Conclusion: These results suggest that SEC possesses some degree of anti-trypanosomal effect, and 
that combination therapy of SEC and DA was superior to DA alone. 
 
Keywords: Trypanosoma, Secnidazole, Diminazene aceturate, Anti-trypanosomal, Combination 
therapy 
 
Tropical Journal  of Pharmaceutical Research is indexed by Science Citation Index (SciSearch), Scopus, 
International Pharmaceutical Abstract, Chemical Abstracts, Embase, Index Copernicus, EBSCO, African 
Index Medicus, JournalSeek, Journal Citation Reports/Science Edition, Directory of Open Access Journals 




Trypanosomiasis is a complex debilitating 
protozoan disease of both man and animal [1]. 
Animal trypanosomiasis is a disease complex 
caused by Trypanosoma congolense, T. vivax, or 
T. brucei brucei, or mixed infection of these 
trypanosomes and transmitted by the tsetse-fly. 
The disease is characterized by intermittent 
fever, anemia, occasional diarrhea, and if 
untreated leads to the death of the infected 
animal [2]. The major chemotherapeutic agent of 
animal trypanosomiasis is diminazene aceturate 
(DA) [3]. Diminazene aceturate also known as 4, 
4' - (1-triazene-1, 3 - diaceturate) is indicated for 
prophylaxis and treatment of trypanosomiasis in 
cattle, dogs, goats, sheep and swine [4]. DA is 
an RNA and DNA binder and is antibacterial and 
antiprotozoal in action [5].  
 
The major setback in the use of DA is relapse 
infection, drug resistance and toxicity.  Relapse 
infection occurs as a result of sequestration of 
trypanosomes in organs and tissues like the 
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brain where DA does not accumulate in 
therapeutic concentrations [6-8]. Therefore there 
is need for identification of agents that can 
improve treatment outcomes and eliminate 
relapse infection. Some 5-nitroimidazoles like 
fexinidazole and benznidazole have been used 
in the treatment of some human forms of 
trypanosomiasis like Chagas diseases in South 
America [9,10]. Chagas disease is a human form 
of trypanosomiasis in South America caused by 
Trypanosoma cruzi. 5–nitroimidazoles are well 
distributed and accumulate in sufficient amounts 
in the brain [10,11]. This is an advantage in the 
treatment of trypanosomiasis. 
 
Secnidazole (SEC) is 1-(2-methyl-5-nitro-1-
imidazol-1-yl) propan-2-ol [12]. The antiprotozoal 
and antiamoebic activities of SEC are due to 
reduction of the nitro group of nitroimidazole by 
ferrodoxin [13]. SEC is completely absorbed after 
oral administration. 5-nitroimidazoles share a 
common spectrum of activity against anaerobic 
micro-organisms and they appear particularly 
effective in the treatment of amoebiasis, 
giardiasis, trichomoniasis and bacterial vaginiasis 
[14]. Secnidazole is safe and well tolerated. Its 
single dose treatments are widely used for 
amoebiasis, giardiasis, trichomoniasis and 
genitourinary infections [14]. The high efficacy of 
SEC in the treatment of these protozoal diseases 
necessitated investigation into wider application 
of this drug specifically in the treatment of T. b. 
brucei infection in animals. To the best of our 
knowledge, there has not been any report on the 
anti-trypanosomal effect of SEC.  
 
Therefore the objective of this study was to 
investigate possible anti-trypanosomal effects of 
SEC in vitro and in vivo. Possible 
chemotherapeutic synergy between SEC and DA 






T. brucei brucei used in this study was originally 
isolated from a mongrel dog presented at the 
Veterinary Teaching Hospital University of 
Nigeria Nsukka. Morphological identification was 
by standard procedures [15]. The parasites were 
maintained in rats from which experimental 




Sixty albino rats were used in this study. They 
were housed in stainless steel cages. Water and 
feed were provided ad libitum. They were 
allowed to acclimatize for 1 week before each 
study. The animal experimental protocol was 
approved by the Experimental Animal Ethics 
Committee of the Faculty of Veterinary medicine, 
University of Nigeria, Nsukka and in compliance 
with the Federation of European Laboratory 
Animal Science Association and the European 
Community Council Directive of November 24, 
1986 (86/609/EEC).  
 
In vitro anti-trypanosomal effect of SEC 
 
This experiment was performed using standard 
protocol for in vitro anti-trypanosomal assay [16, 
17]. Aqueous suspension (100 µl) of SEC 
concentration (125 mg/ml) in distilled water was 
pipetted into microtiter wells. Serial double 
dilutions of the drug suspension were prepared in 
the microwells to obtain a final volume of 50 µl in 
each well. Forty five (45) µl of trypanosome-
infected blood containing about 225,000 
trypanosomes suspended in phosphate saline 
glucose (PSG) as nutrient medium was added to 
each well containing the SEC suspension and 
the final concentration of SEC in each well was 
determined. The same procedure was repeated 
for DA. As control, 50 µl of PSG was pipetted 
into another well. The set up was incubated for 1 
h at 37 oC.  
 
For assessment of anti-trypanosomal activity, 5 
µl of each sample was taken at 10 min intervals, 
and placed on a microscope slide covered with a 
cover slip and viewed under the microscope for 
trypanosome motility. Total inhibition of 
trypanosome motility was considered 
trypanocidal. The minimum drug concentration 
that totally inhibited trypanosome motility within 1 
h was taken as the minimum inhibitory 
concentration (MIC) of the drug. 
 
Infection of rats 
 
Parasitemia was estimated using the rapid 
matching technique [18]. All rats were infected 
intraperitoneally (i.p.)  using 1 x 106 T. b. brucei 
suspended in 0.2 ml of phosphate buffered saline 
(PBS). The rats were monitored daily for onset of 
parasitemia using wet mount.  
 
Dose-response effect of SEC in T. b. brucei-
infected rats 
 
Twenty five rats randomly assigned to 5 groups 
(A – E) of 5 rats each were used in this 
experiment. They were grouped as follows: A: 
infected untreated, B: infected and treated once 
with DA (3.5 mg/kg) IP; groups C, D and E were 
infected and treated orally with 400, 800 and 
1600 mg/kg SEC respectively for six consecutive 
days. Parasitemia was monitored daily using the 
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rapid matching technique [18]. Treatment started 
on day 5 post-infection (PI). Changes in 
parasitemia were recorded and daily mean 
 parasitemia was calculated for each group. 
 
Effect of combination therapy of SEC and DA 
on parasitemia in T. b. brucei-infected rats 
 
Thirty-five rats randomly assigned to 7 groups of 
five rats per group were used. They were 
grouped as follows: 1: infected untreated; 2 - 7: 
infected and treated with DA (3.5 mg/kg) IP once; 
3 - 7: infected and treated in addition with DA, 
50, 100, 200, 400 and 800 mg/kg SEC orally 
respectively for six consecutive days. 
Parasitemia was established 5 days post-
infection and treatment started on day 8 post-
infection. The following parameters were 
monitored: daily parasitemia, time of clearance of 
parasitemia and time of relapse of infection.  The 
animals were monitored for 70 days post-
treatment for relapse infection. Groups that did 
not relapse by day 70 were considered cured. 
 
Statistical analysis  
 
The data collected are presented as mean ± 
SEM. Analyses of data on parasitemia were 
done using repeated measure ANOVA. Variant 
means were separated using least significant 







In vitro trypanocidal effects of secnidazole 
and diminazene aceturate 
 
SEC at concentrations of 2.8 and 1.4 mg/ml 
eliminated trypanosome motility within 10 min of 
incubation. Lower concentrations of SEC had no 
visible effect on trypanosome motility. Elimination 
of trypanosome motility also occurred within the 
same period for DA concentrations of 0.267 to 
0.0041 mg/ml. DA at 0.0021 mg/ml eliminated 
trypanosome motility 20 min post-incubation 
while the controls (phosphate saline glucose) 
had no visible effect on the trypanosome 
parasites (Table 1). 
 
Dose-response effect of SEC on parasitemia 
in T. brucei brucei- infected rats 
 
There was no significant (p > 0.05) variation in 
the levels of parasitemia on day 5 post-infection 
(PI) in all the groups. However, from day 6 PI to 
the end of the experiment, all treated rats 
showed significantly (p < 0.05) lower levels of 
parasitemia than the infected untreated group 
except for the SEC (400 mg/kg) on days 7 and 8 
PI. There was no significant variation in 
parasitemia between the SEC and DA treated 
groups on days 5, 6 and 7 PI; nevertheless 
parasitemia was significantly (p < 0.05) lower in 
the DA treated group on days 8 and 9 and by day 
10 PI, the parasites were completely cleared 
from the blood in this group as opposed to SEC 
treated groups (Figure 1). 
 
Table 1: In vitro antitrypanosomal effects of SEC and DA 
 
Secnidazole concentrations (mg/ml) Incubation time (min) 
10 20 30 40 50 60 
2.8 -      
1.4 -      
0.7 + + + + + + 
Phosphate saline glucose + + + + + + 
Diminazene aceturate concentration 
(mg/ml) 
      
0.264 -      
0.134 -      
0.067 -      
0.033 -      
0.017 -      
0.0084 -      
0.0041 -      
0.0021 + -     
0.001 + + + + + + 
Phosphate saline glucose + + + + + + 
(+) = parasites were motile; (-) = parasites were immotile 
 
Eke et al 




Figure 1: Effect of SEC on parasitemia in rats infected with T. brucei brucei. Note: Log parasitemia below 5.4 
shows undetectable parasitemia 
 
Effect of combination therapy of sec on 
parasitemia in T. b. brucei infected rats 
 
There was no significant variation in parasitemia 
on day 8. However, on day 9, groups 4 and 5 
had significantly (p < 0.05) lower parasitemia 
than groups 1 and 2. In addition, group 6 had 
significantly (p < 0.05) lower parasitemia than 
group 3. From day 10 onwards all the treated 
groups had significantly (p < 0.05) lower 
parasitemia than the untreated.  Relapse of 
infection occurred in group 2 on day 21, in group 
3 on day 24, and on day 35 PI for group 4. By 
day 20 PI all untreated rats had died. There was 
no relapse of infection in groups 5, 6 and 7 up to 





Figure 2: Effects of combination therapy of SEC and DA on parasitemia in rats infected with T. brucei brucei. 
Note: Mean log parasitemia below 5.4 indicates undetectable parasitemia.The arrows show points of relapse 
(reappearance of parasites in the blood after initial disappearance following treatment). Data collection on 
parasitemia was terminated as soon as relapse was recorded for any group. Animals that did not relapse by day 
70 PI are assumed to be cured 
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In the present study, SEC showed promising in 
vitro trypanocidal efficacy at concentrations of 
2.8 and 1.4 mg/ml. In rats the effect of SEC was 
dose-dependent with significant anti-
trypanosomal effect. In combination with DA, 
earlier clearance of parasite was achieved and 
relapse of infection was prevented at higher 
doses of SEC. The MIC of SEC was very high 
when compared with DA. This may suggest that 
higher doses of SEC would be required to 
produce anti-trypanosomal effects in vivo. The 
SEC-induced death of trypanosomes shows that 
trypanosomes are sensitive to the antimicrobial 
effects of SEC. However, it seems that for 
optimum drug uptake by trypanosome, SEC has 
to be available in high concentrations. 
Furthermore the effect of SEC did not appear to 
be time-dependent; rather it was concentration-
dependent. Therefore further investigation of 
SEC for in vivo effect was necessary. 
 
The dose-response effect of SEC in rats showed 
that SEC has significant anti-trypanosomal effect 
which was dose dependent. However SEC was 
not able to completely eliminate trypanosomes at 
all doses used within the period of the study. All 
SEC-treated groups maintained a low grade 
steady state parasitemia throughout the period of 
treatment. However by day 10 PI, there was a 
surge of parasitemia in all SEC-treated groups, 
while parasitemia cleared completely in the DA-
treated group. The anti-trypanosomal effect of 
SEC as observed in this study appears to be 
trypanostatic in action and may require a 
functional immune system for total clearance of 
parasitemia. It is known that trypanosomiasis 
cause severe immunosuppression [19]. This may 
explain the persistent and subsequent surge of 
parasitemia on day 10 PI. This resurgence of 
parasitemia could be due to progressive 
immunosuppression by trypanosomes and 
increased multiplication of the trypanosomes. 
Antiprotozoal activity of SEC is by reduction of 
nitro group of nitroimidazole by ferrodoxin.  
 
The nitro group of secnidazole is reduced to 
intermediate compounds in microorganisms 
which cause cytotoxicity by damaging DNA [13]. 
It is not clear whether or not this mechanism is 
involved in the anti-trypanosomal effect of SEC. 
Howver, it is clear from this study that 
trypanosomes are sensitive to some 
antimicrobial effects of SEC. Thus for full 
exploitation of the observed antitrypanosomal 
effects of SEC, further studies in the area of 
combination therapy with other potent 
trypanocidal drugs like DA was necessary. 
 
Combination therapies are used either to obtain 
synergism or reduce incidence of drug resistance 
and toxicity or reduce the incidence and severity 
of adverse drug reactions [6]. The combined 
therapy of SEC and DA in rats infected with T. b. 
brucei was more effective than mono-therapy of 
DA. There was faster clearance of parasitemia in 
all the combined therapy groups than the DA 
group. Parasitemia cleared in all the combined 
treatment groups after 3 days of treatment, while 
it cleared 5 days post-treatment with DA. 
Furthermore, relapse of infection occurred in the 
DA treated rats 13 days post-treatment; this 
occurred in the 50 and 100 mg/kg SEC 
combination groups 16 and 27 days post-
treatment, respectively.  
 
There was no relapse of infection in the 200, 400 
and 800 mg/kg SEC combination groups up to 
day 70 post-treatment when the experiment 
terminated. It has been established that 
treatment of experimental T. b. brucei infection in 
animals becomes less effective as time interval 
between infection and treatment increases [20]. 
A possible explanation for this is the presence of 
trypanosomes in drug-inaccessible sites like the 
brain [21]. Treatment was initiated 8 days PI, 
which was 3 days post-confirmation of 
parasitemia. It appears that, the time interval 
between infection and treatment was long 
enough to allow trypanosomes to invade the 
brain, thus the relapse of infection. However, it 
appears that the combination of SEC at higher 
doses with DA lead to higher therapeutic drug 
concentration in the brain and other drug 
inaccessible sites, thereby preventing relapse of 
infection.  
 
The effectiveness of SEC at higher doses could 
explain the high MIC observed in the in vitro 
assay. Furthermore, our findings suggest 
possible chemotherapeutic synergy between 
SEC and DA. However, the degree of 
effectiveness of this combination is dependent on 
the dose of SEC combined with 3.5 mg/kg DA. 
Lower doses of SEC combined with DA, though 
more effective than mono-therapy of DA, were 
not able to prevent relapse of infection. From this 
study, the lowest dose of SEC that can be 
combined with DA to prevent relapse of infection 




In vitro, SEC has been shown to possess anti-
trypanosomal activity. In vivo, SEC exhibited a 
dose-dependent anti-trypanosomal effect. 
Combination therapy of SEC and DA prevented 
relapse of infection and was more efficacious 
than DA alone.   The outcome of this study may 
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be very important in the treatment of 
trypanosomiasis in dogs, especially exotic 
breeds that reside in trypanosome-endemic 
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